Foghorn Therapeutics Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
FHTX Nasdaq 8731 https://foghorntx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - Mar 9th, 2023 1:35 pm
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update - Mar 9th, 2023 12:00 pm
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference - Mar 1st, 2023 1:00 pm
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week - Feb 16th, 2023 6:49 pm
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023 - Jan 9th, 2023 12:00 pm
Foghorn Therapeutics (NASDAQ:FHTX) shareholders have endured a 72% loss from investing in the stock a year ago - Dec 21st, 2022 10:19 am
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting - Dec 5th, 2022 12:00 pm
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference - Nov 22nd, 2022 1:00 pm
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting - Nov 14th, 2022 12:00 pm
Foghorn Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag - Nov 10th, 2022 10:18 am
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting - Nov 9th, 2022 12:00 pm
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates - Nov 8th, 2022 1:15 pm
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update - Nov 8th, 2022 12:00 pm
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors - Oct 27th, 2022 11:00 am
Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect? - Oct 26th, 2022 1:55 pm
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program - Oct 26th, 2022 11:00 am
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit - Oct 20th, 2022 11:00 am
Institutional investors own a significant stake of 37% in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Oct 16th, 2022 2:45 pm
Foghorn Therapeutics to Participate in the Bank of America 2022 Precision Oncology Conference - Sep 27th, 2022 12:00 pm
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences - Sep 1st, 2022 8:05 pm